$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Combined TGE-SGE Expression of Novel PAI-1-Resistant t-PA in CHO DG44 Cells Using Orbitally Shaking Disposable Bioreactors 원문보기

Journal of microbiology and biotechnology, v.21 no.12, 2011년, pp.1299 - 1305  

Davami, Fatemeh (Biotechnology Research Center, Pasteur Institute of Iran) ,  Barkhordari, Farzaneh (Biotechnology Research Center, Pasteur Institute of Iran) ,  Alebouyeh, Mahmoud (Biotechnology Research Center, Pasteur Institute of Iran) ,  Adeli, Ahmad (Biotechnology Research Center, Pasteur Institute of Iran) ,  Mahboudi, Fereidoun (Biotechnology Research Center, Pasteur Institute of Iran)

Abstract AI-Helper 아이콘AI-Helper

An important modification of thrombolytic agents is resistance to plasminogen activator inhibitor-1 (PAI-1). In previous studies, a new truncated PAI-1-resistant variant was developed based on deletion of the first three domains in t-PA and the substitution of KHRR 128-131 amino acids with AAAA in t...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

제안 방법

  • Accordingly, this study explored the expression of the truncated-mutant t-PA in CHO DG44 cells when combining features from transient and stable transfection [5] in an orbitally shaking disposable bioreactor (TubeSpin, TPP Trasadingen, Switzerland), plus a rapid approach for producing the truncated-mutant t-PA is developed.
  • 2/blunt Cloning Vector, using a CloneJET PCR Cloning Kit from Fermentas (Lithuania) based on the manufacturer’s procedures. After confirming the proper sequence arrangement by bidirectional sequencing, two upstream and downstream BglII restriction sites of pJET were used for cloning into the EcoRV site in pTracer-SV40 (CHO expression vector). The BglII sticky ends were converted to blunt ends using the CloneJET PCR Cloning Kit DNA blunting enzyme.
  • As a result, a novel truncated form of t-PA with an improved fibrin affinity was expressed in a CHO DG44 expression system [9]. As a further improvement, a PAI-1-resistant novel form of the truncated t-PA was also designed. The truncated mutant variant was then successfully expressed in CHO DG44 and showed an increased resistance to PAI-1 [8].
  • The clones were tested for their expression of the t-PA protein. Positive clones were expanded into large wells and then into flasks or plates, and re-tested to confirm their expression.
  • SDS-PAGE (12%) was carried out under reduced conditions and the Coomassie Blue-stained gel scanned using a densitometer (Bio-Rad) to determine the expression level of the truncated mutant t-PA in the culture supernatant.
  • The CHO DG44 cells were stably transfected with the truncated mutant t-PA-p-Tracer-SV40 recombinant plasmid based on the optimized Lipofectamine:DNA ratio mentioned above, and the supernatant was harvested on different days (day 3, day 6, day 9, and day 11) after the transfection. The expression of the fusion protein on day 7 was analyzed by SDS-PAGE.
  • The supernatant from the static and suspension cultures was sampled on different days throughout the experiment to assess the protein production kinetics. An ELISA-based biofunctional immunosorbent assay with a Biopool Chromolize t-PA assay kit was used to quantify the truncated-mutant t-PA.
본문요약 정보가 도움이 되었나요?

참고문헌 (34)

  1. American Heart Association. 2008. Heart Disease and Stroke Statistics. Accessible at http://www.americanheart.org/downloadable/ heart/1200082005246HS_Stats%202008.final.pdf. 

  2. Backliwal, G., M. Hildinger, S. Chenuet, S. Wulhfard, J. M. De, and F. M. Wurm. 2008. Rational vector design and multipathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36: e96. 

  3. Baldi, L., D. L. Hacker, M. Adam, and F. M. Wurm. 2007. Recombinant protein production by large-scale transient gene expression in mammalian cells: State of the art and future perspectives. Biotechnol. Lett. 29: 677-684. 

  4. Baruah, D. B., R. N. Dash, M. R. Chaudhari, and S. S. Kadam. 2006. Plasminogen activators: A comparison. Vascul. Pharmacol. 44: 1-9. 

  5. Benavides Damm, T. and F. M. Wurm. 2010. Generation of the stable cell line for the production of theraputic proteins using the Piggy Back transposon for transgene delivery. Master Thesis Project. 

  6. Benchenane, K., J. P. Lopez-Atalaya, M. Fernandez-Monreal, O. Touzani, and D. Vivien. 2004. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27: 155-160. 

  7. Burck, P. J., D. H. Berg, M. W. Warrick, D. T. Berg, J. D. Walls, S. R. Jaskunas, et al. 1990. Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain. J. Biol. Chem. 265: 5170-5177. 

  8. Davami, F., S. Sardari, A. Majidzadeh, M. Hemayatkar, F. Barkhordari, S. Enayati, et al. 2011. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments. BMB Rep. 44: 34-39. 

  9. Davami, F., S. Sardari, A. Majidzadeh, M. Hemayatkar, F. Barkhrdari, M. Omidi, et al. 2010. Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments. J. Biomed. Biotechnol. 2010: 108159. 

  10. Erickson, L. A., M. H. Ginsberg, and D. J. Loskutoff. 1984. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J. Clin. Invest. 74: 1465-1472. 

  11. Hemayatkar, M., F. Mahboudi, A. Majidzadeh, F. Davami, B. Vaziri, F. Barkhordari, et al. 2010. Increased expression of recombinant human tissue plasminogen activator in Leishmania tarentolae. Biotechnol. J. 5: 1198-1206. 

  12. Krishnamurti, C. and B. M. Alving. 1992. Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin. Thromb. Hemost. 18: 67-80. 

  13. Krishnamurti, C., B. Keyt, P. Maglasang, and B. M. Alving. 1996. PAI-1-resistant t-PA: Low doses prevent fibrin deposition in rabbits with increased PAI-1 activity. Blood 87: 14-19. 

  14. Krishnamurti, C., G. D. Young, C. F. Barr, C. A. Colleton, and B. M. Alving. 1991. Enhancement of tissue plasminogen activatorinduced fibrinolysis by activated protein C in endotoxin-treated rabbits. J. Lab. Clin. Med. 118: 523-530. 

  15. Li, X. K., H. R. Lijnen, L. Nelles, H. B. Van, J. M. Stassen, and D. Collen. 1992. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 79: 417-429. 

  16. Majidzadeh, A., V. Khalaj, D. Fatemeh, H. Mahdi, B. Farzaneh, A. Ahmad, and F. Mahboudi. 2010. Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris. Appl. Biochem. Biotechnol. 162: 2037-2048. 

  17. Mitsuyama, K., M. Sata, and S. Rose-John. 2006. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 17: 451-461. 

  18. Nordt, T. K. and C. Bode. 2003. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Heart 89: 1358-1362. 

  19. Novick, D. and M. Rubinstein. 2007. The tale of soluble receptors and binding proteins: From bench to bedside. Cytokine Growth Factor Rev. 18: 525-533. 

  20. Paoni, N. F., B. A. Keyt, C. J. Refino, A. M. Chow, H. V. Nguyen, L. T. Berleau, et al. 1993. A slow clearing, fibrinspecific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb. Haemost. 70: 307-312. 

  21. Pennica, D., W. E. Holmes, W. J. Kohr, R. N. Harkins, G. A. Vehar, C. A. Ward, et al. 1983. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301: 214-221. 

  22. Pham, P. L., A. Kamen, and Y. Durocher. 2006. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol. Biotechnol. 34: 225-237. 

  23. Ranby, M., N. Bergsdorf, G. Pohl, and P. Wallen. 1982. Isolation of two variants of native one-chain tissue plasminogen activator. FEBS Lett. 146: 289-292. 

  24. Rubin, L. A., C. C. Kurman, M. E. Fritz, W. E. Biddison, B. Boutin, R. Yarchoan, and D. L. Nelson. 1985. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135: 3172-3177. 

  25. Shohet, R. V., S. Spitzer, E. L. Madison, R. Bassel-Duby, M. J. Gething, and J. F. Sambrook. 1994. Inhibitor-resistant tissuetype plasminogen activator: An improved thrombolytic agent in vitro. Thromb. Haemost. 71: 124-128. 

  26. Soleimani, M., F. Mahboudi, N. Davoudi, A. Amanzadeh, M. Azizi, A. Adeli, et al. 2007. Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae. Biotechnol. Appl. Biochem. 48: 55-61. 

  27. Sporri, B., M. Bickel, D. Dobbelaere, J. Machado Jr., and D. Lottaz. 2001. Soluble interleukin-1 receptor - reverse signaling in innate immunoregulation. Cytokine Growth Factor Rev. 12: 27-32. 

  28. Stettler, M., X. Zhang, D. L. Hacker, J. M. De, and F. M. Wurm. 2007. Novel orbital shake bioreactors for transient production of CHO derived IgGs. Biotechnol. Prog. 23: 1340- 1346. 

  29. Truelsen, T. and R. Bonita. 2003. Advances in ischemic stroke epidemiology. Adv. Neurol 92: 1-12. 

  30. Varley, J. and J. Birch. 1999. Reactor design for large-scale suspension animal cell culture. Cytotechnology 29: 177-205. 

  31. Wagner, O. F., C. de Vries, C. Hohmann, H. Veerman, and H. Pannekoek. 1989. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J. Clin. Invest. 84: 647-655. 

  32. Weaver, W. D. 1996. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur. Heart J. 17 Suppl F: 9-15. 

  33. Wurm, F. and A. Bernard. 1999. Large-scale transient expression in mammalian cells for recombinant protein production. Curr. Opin. Biotechnol. 10: 156-159. 

  34. Wurm, F. M. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22: 1393-1398. 

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로